Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03608826 · ClinicalTrials.gov registry record · NA

Relationship Between LINQ™ Subcutaneous Impedance and Right-sided Hemodynamic Measurements

A NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

Completed
Registry status
NA
Development phase
12
Enrollment target

NCT03608826 is a NA study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03608826, a NA study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target

Study Summary

The purpose of the ReLINQuish study is to characterize the relationship between subcutaneous impedance and hemodynamic measurements in patients with heart failure. Additionally, the relationship between changes in subcutaneous impedance and other physiologic parameters during acute decompensated HF events will be characterized.

Interventions

  • DEVICE Investigational LINQ™ HF RAMware

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2018-07-13
Est. Completion 2021-05-07
Phase NA

What the Registry Record Tells You About NCT03608826

The ClinicalTrials.gov registry entry for NCT03608826 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Investigational LINQ™ HF RAMware is the first listed.

NCT03608826 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03608826 about?

NCT03608826 is a clinical study titled "Relationship Between LINQ™ Subcutaneous Impedance and Right-sided Hemodynamic Measurements". The purpose of the ReLINQuish study is to characterize the relationship between subcutaneous impedance and hemodynamic measurements in patients with heart failure. Additionally, the relationship between changes in subcutaneous impedance and other physiologic parameters during acute decompensated HF ...

What is the current status of trial NCT03608826?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2018-07-13. Estimated completion is 2021-05-07.

What interventions are being tested in trial NCT03608826?

The interventions under investigation include: Investigational LINQ™ HF RAMware (DEVICE).

Who is sponsoring clinical trial NCT03608826?

This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.